For any item to be covered by Medicare, it must 1) be eligible for a defined
Medicare benefit category, 2) be reasonable and necessary for the diagnosis or
treatment of illness or injury or to improve the functioning of a malformed
body member, and 3) meet all other applicable Medicare statutory and
regulatory requirements.  
  
The purpose of a Local Coverage Determination (LCD) is to provide information
regarding "reasonable and necessary" criteria based on Social Security Act 
1862(a)(1)(A) provisions.  
  
In addition to the "reasonable and necessary" criteria contained in this LCD
there are other payment rules, which are discussed in the following documents,
that must also be met prior to Medicare reimbursement:

  * The LCD-related Standard Documentation Requirements Article, located at the bottom of this policy under the Related Local Coverage Documents section.
  * The LCD-related Policy Article, located at the bottom of this policy under the Related Local Coverage Documents section.
  * Refer to the Supplier Manual for additional information on documentation requirements.
  * Refer to the DME MAC web sites for additional bulletin articles and other publications related to this LCD.

For the items addressed in this LCD, the "reasonable and necessary" criteria,
based on Social Security Act  1862(a)(1)(A) provisions, are defined by the
following coverage indications, limitations and/or medical necessity.  
  
The use of the oral anti-emetic 3-drug combination of an FDA approved oral
NK-1 antagonist in combination with an oral 5HT3 antagonist and dexamethasone
(J8540) is covered if, in addition to meeting the statutory coverage criteria
specified in the related Policy Article, they are administered to
beneficiaries who are receiving one or more of the following anti-cancer
chemotherapeutic agents:

  * Alemtuzumab
  * Azacitidine
  * Bendamustin
  * Carboplatin
  * Carmustine
  * Cisplatin
  * Clofarabine
  * Cyclophosphamide
  * Cytarabine
  * Dacarbazine
  * Daunorubicin
  * Doxorubicin
  * Epirubicin
  * Idarubicin
  * Ifosfamide
  * Irinotecan
  * Lomustine
  * Mechlorethamine
  * Oxaliplatin
  * Streptozocin

If the NK-1 antagonist, 5HT3 antagonist and dexamethasone 3-drug combination
meet the statutory coverage criteria, but are not used with one of the
preceding chemotherapeutic agents, they will be denied as not reasonable and
necessary.  
  
An NK-1 antagonist and/or dexamethasone are only covered as an oral antiemetic
regimen when administered as the 3-drug regimen described above. The 3-drug
regimen is available in differing preparations as single drugs or in multi-
drug combinations. All drugs must be billed on the same claim. Refer to the
POLICY SPECIFIC DOCUMMENTATION REQUIREMENTS and the CODING GUIDELINES section
of the related Policy Article for specific instructions. Billing for these
drugs on separate claims will be denied as not reasonable and necessary,
incorrect billing.  
  
The supplier may dispense only a single course of oral antiemetic drugs at one
time unless it is known there will be more than a single course of
chemotherapy in the month, in which case the supplier may dispense no more
than a single month's supply.  
  
Drugs may be covered only if dispensed and billed to Medicare by the entity
that actually dispenses the drug to the Medicare beneficiary, and that entity
must be permitted under all applicable federal, state, and local laws and
regulations to dispense drugs. Only entities licensed in the state where they
are physically located may bill for oral antiemetic drugs (CMS Benefit Policy
Manual, Internet-Only Manual, CMS Pub. 100-02, Chapter 15, Section 110.3).
Treating practitioners  may bill the DME MAC for drugs if all of the following
conditions are met: the treating practitioner is 1) enrolled as a DMEPOS
supplier with the National Supplier Clearinghouse, and 2) dispensing the
drug(s) to the Medicare beneficiary, and 3) authorized by the State to
dispense drugs as part of the treating practitioner's license. Claims
submitted by entities not licensed to dispense drugs will be denied for lack
of medical necessity.  
  
If the drug on the claim is denied as not reasonable and necessary, the supply
fee will be denied as not reasonable and necessary.  
  
Refer to the Oral Anticancer Drugs policy for information on coverage of
antiemetic drugs used in conjunction with oral anticancer drugs.  
  
  
GENERAL  
  

A Standard Written Order (SWO) must be communicated to the supplier before a
claim is submitted. If the supplier bills for an item addressed in this policy
without first receiving a completed SWO, the claim shall be denied as not
reasonable and necessary.

For Durable Medical Equipment, Prosthetics, Orthotics and Supplies (DMEPOS)
base items that require a Written Order Prior to Delivery (WOPD), the supplier
must have received a signed SWO before the DMEPOS item is delivered to a
beneficiary. If a supplier delivers a DMEPOS item without first receiving a
WOPD, the claim shall be denied as not reasonable and necessary. Refer to the
LCD-related Policy Article, located at the bottom of this policy under the
Related Local Coverage Documents section.

For DMEPOS base items that require a WOPD, and also require separately billed
associated options, accessories, and/or supplies, the supplier must have
received a WOPD which lists the base item and which may list all the
associated options, accessories, and/or supplies that are separately billed
prior to the delivery of the items. In this scenario, if the supplier
separately bills for associated options, accessories, and/or supplies without
first receiving a completed and signed WOPD of the base item prior to
delivery, the claim(s) shall be denied as not reasonable and necessary.

An item/service is correctly coded when it meets all the coding guidelines
listed in CMS HCPCS guidelines, LCDs, LCD-related Policy Articles, or DME MAC
articles. Claims that do not meet coding guidelines shall be denied as not
reasonable and necessary/incorrectly coded.

Proof of delivery (POD) is a Supplier Standard and DMEPOS suppliers are
required to maintain POD documentation in their files. Proof of delivery
documentation must be made available to the Medicare contractor upon request.
All services that do not have appropriate proof of delivery from the supplier
shall be denied as not reasonable and necessary.

  
  
REFILL REQUIREMENTS  
  
For DMEPOS items and supplies provided on a recurring basis, billing must be
based on prospective, not retrospective use. For DMEPOS products that are
supplied as refills to the original order, suppliers must contact the
beneficiary, and document an affirmative response, prior to dispensing the
refill and not automatically ship on a pre-determined basis, even if
authorized by the beneficiary. This shall be done to ensure that the refilled
item remains reasonable and necessary, existing supplies are expected to end,
and to confirm any changes or modifications to the order. Contact with the
beneficiary or designee regarding refills must take place no sooner than 30
calendar days prior to the expected end of the current supply. For delivery of
refills, the supplier must deliver the DMEPOS product no sooner than 10
calendar days prior to the expected end of the current supply. This is
regardless of which delivery method is utilized.  
  
For all DMEPOS items that are provided on a recurring basis, suppliers are
required to have contact with the beneficiary or caregiver/designee and
document an affirmative response, prior to dispensing a new supply of items.
Suppliers must not deliver refills without a refill request and an affirmative
response from a beneficiary. Items delivered without a valid, documented
refill request will be denied as not reasonable and necessary.  
  
Suppliers must not dispense a quantity of supplies exceeding a beneficiary's
expected utilization. Suppliers must stay attuned to changed or atypical
utilization patterns on the part of their clients. Suppliers must verify with
the treating practitioners  that any changed or atypical utilization is
warranted.  
  
Regardless of utilization, a supplier must not dispense more than a one (1) -
month quantity at a time.

NA

NA